nodes	percent_of_prediction	percent_of_DWPC	metapath
Nefazodone—ABCB1—kidney cancer	0.147	1	CbGaD
Nefazodone—CYP3A7—Temsirolimus—kidney cancer	0.052	0.0858	CbGbCtD
Nefazodone—CYP3A7-CYP3A51P—Temsirolimus—kidney cancer	0.052	0.0858	CbGbCtD
Nefazodone—CYP3A5—Temsirolimus—kidney cancer	0.039	0.0643	CbGbCtD
Nefazodone—ABCB1—Temsirolimus—kidney cancer	0.0254	0.0419	CbGbCtD
Nefazodone—HTR2C—Sorafenib—kidney cancer	0.0243	0.0401	CbGbCtD
Nefazodone—CYP2D6—Temsirolimus—kidney cancer	0.0239	0.0395	CbGbCtD
Nefazodone—CYP3A4—Everolimus—kidney cancer	0.0225	0.0371	CbGbCtD
Nefazodone—CYP3A7-CYP3A51P—Paclitaxel—kidney cancer	0.0178	0.0294	CbGbCtD
Nefazodone—CYP3A7—Paclitaxel—kidney cancer	0.0178	0.0294	CbGbCtD
Nefazodone—CYP3A7—Sorafenib—kidney cancer	0.0159	0.0261	CbGbCtD
Nefazodone—CYP3A7-CYP3A51P—Sorafenib—kidney cancer	0.0159	0.0261	CbGbCtD
Nefazodone—CYP3A7-CYP3A51P—Vincristine—kidney cancer	0.0154	0.0254	CbGbCtD
Nefazodone—CYP3A7—Vincristine—kidney cancer	0.0154	0.0254	CbGbCtD
Nefazodone—CYP3A4—Temsirolimus—kidney cancer	0.0152	0.0251	CbGbCtD
Nefazodone—CYP3A5—Erlotinib—kidney cancer	0.0146	0.0241	CbGbCtD
Nefazodone—CYP3A5—Paclitaxel—kidney cancer	0.0134	0.0221	CbGbCtD
Nefazodone—ABCB1—Pazopanib—kidney cancer	0.0133	0.022	CbGbCtD
Nefazodone—CYP3A7-CYP3A51P—Sunitinib—kidney cancer	0.0128	0.0212	CbGbCtD
Nefazodone—CYP3A7—Sunitinib—kidney cancer	0.0128	0.0212	CbGbCtD
Nefazodone—CYP2D6—Pazopanib—kidney cancer	0.0126	0.0207	CbGbCtD
Nefazodone—ABCB1—Dactinomycin—kidney cancer	0.0122	0.0201	CbGbCtD
Nefazodone—CYP3A5—Sorafenib—kidney cancer	0.0119	0.0196	CbGbCtD
Nefazodone—CYP3A5—Vincristine—kidney cancer	0.0115	0.019	CbGbCtD
Nefazodone—ABCB1—Gemcitabine—kidney cancer	0.00964	0.0159	CbGbCtD
Nefazodone—CYP3A5—Sunitinib—kidney cancer	0.00963	0.0159	CbGbCtD
Nefazodone—ABCB1—Erlotinib—kidney cancer	0.00952	0.0157	CbGbCtD
Nefazodone—CYP2D6—Erlotinib—kidney cancer	0.00897	0.0148	CbGbCtD
Nefazodone—ABCB1—Paclitaxel—kidney cancer	0.00871	0.0144	CbGbCtD
Nefazodone—CYP3A4—Pazopanib—kidney cancer	0.00799	0.0132	CbGbCtD
Nefazodone—ABCB1—Sorafenib—kidney cancer	0.00774	0.0128	CbGbCtD
Nefazodone—ABCB1—Vinblastine—kidney cancer	0.00764	0.0126	CbGbCtD
Nefazodone—ABCB1—Vincristine—kidney cancer	0.00751	0.0124	CbGbCtD
Nefazodone—CYP2D6—Sorafenib—kidney cancer	0.00729	0.012	CbGbCtD
Nefazodone—CYP2D6—Vinblastine—kidney cancer	0.0072	0.0119	CbGbCtD
Nefazodone—ABCB1—Sunitinib—kidney cancer	0.00627	0.0103	CbGbCtD
Nefazodone—CYP3A4—Erlotinib—kidney cancer	0.0057	0.0094	CbGbCtD
Nefazodone—CYP3A4—Paclitaxel—kidney cancer	0.00522	0.00861	CbGbCtD
Nefazodone—ABCB1—Doxorubicin—kidney cancer	0.0047	0.00774	CbGbCtD
Nefazodone—CYP3A4—Sorafenib—kidney cancer	0.00464	0.00765	CbGbCtD
Nefazodone—CYP3A4—Vinblastine—kidney cancer	0.00458	0.00755	CbGbCtD
Nefazodone—CYP3A4—Vincristine—kidney cancer	0.0045	0.00742	CbGbCtD
Nefazodone—CYP2D6—Doxorubicin—kidney cancer	0.00442	0.0073	CbGbCtD
Nefazodone—CYP3A4—Sunitinib—kidney cancer	0.00376	0.00619	CbGbCtD
Nefazodone—CYP3A4—Doxorubicin—kidney cancer	0.00281	0.00464	CbGbCtD
Nefazodone—HTR2A—urine—kidney cancer	0.000774	0.0895	CbGeAlD
Nefazodone—CYP3A4—urine—kidney cancer	0.000717	0.0829	CbGeAlD
Nefazodone—CYP2D6—urine—kidney cancer	0.000705	0.0815	CbGeAlD
Nefazodone—CYP3A7-CYP3A51P—nephron tubule—kidney cancer	0.000621	0.0718	CbGeAlD
Nefazodone—CYP3A7-CYP3A51P—cortex of kidney—kidney cancer	0.000531	0.0614	CbGeAlD
Nefazodone—ADRA1B—renal system—kidney cancer	0.000521	0.0603	CbGeAlD
Nefazodone—ADRA1B—kidney—kidney cancer	0.000504	0.0583	CbGeAlD
Nefazodone—HTR1A—renal system—kidney cancer	0.000318	0.0367	CbGeAlD
Nefazodone—ADRA1A—renal system—kidney cancer	0.000293	0.0339	CbGeAlD
Nefazodone—SLC6A2—gonad—kidney cancer	0.000283	0.0327	CbGeAlD
Nefazodone—CYP3A5—nephron tubule—kidney cancer	0.000257	0.0297	CbGeAlD
Nefazodone—CYP3A5—renal system—kidney cancer	0.000234	0.027	CbGeAlD
Nefazodone—CYP3A5—kidney—kidney cancer	0.000226	0.0261	CbGeAlD
Nefazodone—CYP3A5—cortex of kidney—kidney cancer	0.00022	0.0254	CbGeAlD
Nefazodone—ADRA2A—cortex of kidney—kidney cancer	0.00021	0.0242	CbGeAlD
Nefazodone—ADRA2A—gonad—kidney cancer	0.0002	0.0231	CbGeAlD
Nefazodone—ADRA2A—cardiac atrium—kidney cancer	0.000199	0.0231	CbGeAlD
Nefazodone—HTR2A—renal system—kidney cancer	0.000189	0.0219	CbGeAlD
Nefazodone—HTR2A—kidney—kidney cancer	0.000183	0.0212	CbGeAlD
Nefazodone—CYP3A4—renal system—kidney cancer	0.000175	0.0203	CbGeAlD
Nefazodone—CYP2D6—renal system—kidney cancer	0.000173	0.0199	CbGeAlD
Nefazodone—HTR2A—gonad—kidney cancer	0.00017	0.0196	CbGeAlD
Nefazodone—CYP3A4—kidney—kidney cancer	0.00017	0.0196	CbGeAlD
Nefazodone—CYP2D6—kidney—kidney cancer	0.000167	0.0193	CbGeAlD
Nefazodone—ABCB1—nephron tubule—kidney cancer	0.000137	0.0158	CbGeAlD
Nefazodone—ABCB1—renal system—kidney cancer	0.000124	0.0144	CbGeAlD
Nefazodone—ABCB1—kidney—kidney cancer	0.00012	0.0139	CbGeAlD
Nefazodone—ABCB1—cortex of kidney—kidney cancer	0.000117	0.0135	CbGeAlD
Nefazodone—ABCB1—gonad—kidney cancer	0.000111	0.0129	CbGeAlD
Nefazodone—Somnolence—Gemcitabine—kidney cancer	9.32e-05	0.000453	CcSEcCtD
Nefazodone—Convulsion—Paclitaxel—kidney cancer	9.32e-05	0.000453	CcSEcCtD
Nefazodone—Affect lability—Doxorubicin—kidney cancer	9.3e-05	0.000452	CcSEcCtD
Nefazodone—Migraine—Doxorubicin—kidney cancer	9.3e-05	0.000452	CcSEcCtD
Nefazodone—Nausea—Everolimus—kidney cancer	9.3e-05	0.000452	CcSEcCtD
Nefazodone—Diarrhoea—Sorafenib—kidney cancer	9.29e-05	0.000451	CcSEcCtD
Nefazodone—Hypertension—Paclitaxel—kidney cancer	9.29e-05	0.000451	CcSEcCtD
Nefazodone—Pruritus—Sunitinib—kidney cancer	9.25e-05	0.000449	CcSEcCtD
Nefazodone—Chest pain—Paclitaxel—kidney cancer	9.16e-05	0.000445	CcSEcCtD
Nefazodone—Arthralgia—Paclitaxel—kidney cancer	9.16e-05	0.000445	CcSEcCtD
Nefazodone—Myalgia—Paclitaxel—kidney cancer	9.16e-05	0.000445	CcSEcCtD
Nefazodone—Anxiety—Paclitaxel—kidney cancer	9.13e-05	0.000443	CcSEcCtD
Nefazodone—Face oedema—Doxorubicin—kidney cancer	9.12e-05	0.000443	CcSEcCtD
Nefazodone—Decreased appetite—Gemcitabine—kidney cancer	9.12e-05	0.000443	CcSEcCtD
Nefazodone—Hypersensitivity—Dactinomycin—kidney cancer	9.12e-05	0.000443	CcSEcCtD
Nefazodone—Chills—Capecitabine—kidney cancer	9.1e-05	0.000442	CcSEcCtD
Nefazodone—Discomfort—Paclitaxel—kidney cancer	9.05e-05	0.00044	CcSEcCtD
Nefazodone—Gastrointestinal pain—Vincristine—kidney cancer	9.04e-05	0.000439	CcSEcCtD
Nefazodone—Dizziness—Sorafenib—kidney cancer	8.98e-05	0.000436	CcSEcCtD
Nefazodone—Constipation—Gemcitabine—kidney cancer	8.97e-05	0.000436	CcSEcCtD
Nefazodone—Pain—Gemcitabine—kidney cancer	8.97e-05	0.000436	CcSEcCtD
Nefazodone—Nausea—Erlotinib—kidney cancer	8.97e-05	0.000436	CcSEcCtD
Nefazodone—Alopecia—Capecitabine—kidney cancer	8.96e-05	0.000435	CcSEcCtD
Nefazodone—Dry mouth—Paclitaxel—kidney cancer	8.96e-05	0.000435	CcSEcCtD
Nefazodone—Mood swings—Doxorubicin—kidney cancer	8.95e-05	0.000435	CcSEcCtD
Nefazodone—Diarrhoea—Sunitinib—kidney cancer	8.94e-05	0.000434	CcSEcCtD
Nefazodone—Ataxia—Doxorubicin—kidney cancer	8.89e-05	0.000432	CcSEcCtD
Nefazodone—Asthenia—Dactinomycin—kidney cancer	8.88e-05	0.000431	CcSEcCtD
Nefazodone—Confusional state—Paclitaxel—kidney cancer	8.85e-05	0.00043	CcSEcCtD
Nefazodone—Dehydration—Doxorubicin—kidney cancer	8.79e-05	0.000427	CcSEcCtD
Nefazodone—Anaphylactic shock—Paclitaxel—kidney cancer	8.78e-05	0.000427	CcSEcCtD
Nefazodone—Oedema—Paclitaxel—kidney cancer	8.78e-05	0.000427	CcSEcCtD
Nefazodone—Abdominal pain—Vincristine—kidney cancer	8.74e-05	0.000425	CcSEcCtD
Nefazodone—Body temperature increased—Vincristine—kidney cancer	8.74e-05	0.000425	CcSEcCtD
Nefazodone—Liver function test abnormal—Doxorubicin—kidney cancer	8.73e-05	0.000424	CcSEcCtD
Nefazodone—Infection—Paclitaxel—kidney cancer	8.72e-05	0.000424	CcSEcCtD
Nefazodone—Flatulence—Capecitabine—kidney cancer	8.7e-05	0.000423	CcSEcCtD
Nefazodone—Dry skin—Doxorubicin—kidney cancer	8.66e-05	0.000421	CcSEcCtD
Nefazodone—Dysgeusia—Capecitabine—kidney cancer	8.65e-05	0.00042	CcSEcCtD
Nefazodone—Dizziness—Sunitinib—kidney cancer	8.64e-05	0.00042	CcSEcCtD
Nefazodone—Feeling abnormal—Gemcitabine—kidney cancer	8.64e-05	0.00042	CcSEcCtD
Nefazodone—Shock—Paclitaxel—kidney cancer	8.64e-05	0.00042	CcSEcCtD
Nefazodone—Vomiting—Sorafenib—kidney cancer	8.64e-05	0.00042	CcSEcCtD
Nefazodone—Orthostatic hypotension—Doxorubicin—kidney cancer	8.63e-05	0.000419	CcSEcCtD
Nefazodone—Thrombocytopenia—Paclitaxel—kidney cancer	8.6e-05	0.000418	CcSEcCtD
Nefazodone—Tachycardia—Paclitaxel—kidney cancer	8.57e-05	0.000416	CcSEcCtD
Nefazodone—Rash—Sorafenib—kidney cancer	8.57e-05	0.000416	CcSEcCtD
Nefazodone—Dermatitis—Sorafenib—kidney cancer	8.56e-05	0.000416	CcSEcCtD
Nefazodone—Back pain—Capecitabine—kidney cancer	8.54e-05	0.000415	CcSEcCtD
Nefazodone—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	8.51e-05	0.000413	CcSEcCtD
Nefazodone—Headache—Sorafenib—kidney cancer	8.51e-05	0.000413	CcSEcCtD
Nefazodone—Muscle spasms—Capecitabine—kidney cancer	8.49e-05	0.000412	CcSEcCtD
Nefazodone—Hyperhidrosis—Paclitaxel—kidney cancer	8.49e-05	0.000412	CcSEcCtD
Nefazodone—Diarrhoea—Dactinomycin—kidney cancer	8.47e-05	0.000411	CcSEcCtD
Nefazodone—Anorexia—Paclitaxel—kidney cancer	8.37e-05	0.000407	CcSEcCtD
Nefazodone—Gastritis—Doxorubicin—kidney cancer	8.36e-05	0.000406	CcSEcCtD
Nefazodone—Alanine aminotransferase increased—Doxorubicin—kidney cancer	8.34e-05	0.000405	CcSEcCtD
Nefazodone—Vision blurred—Capecitabine—kidney cancer	8.32e-05	0.000404	CcSEcCtD
Nefazodone—Vomiting—Sunitinib—kidney cancer	8.31e-05	0.000404	CcSEcCtD
Nefazodone—Body temperature increased—Gemcitabine—kidney cancer	8.29e-05	0.000403	CcSEcCtD
Nefazodone—Tremor—Capecitabine—kidney cancer	8.27e-05	0.000402	CcSEcCtD
Nefazodone—Rash—Sunitinib—kidney cancer	8.24e-05	0.0004	CcSEcCtD
Nefazodone—Dermatitis—Sunitinib—kidney cancer	8.23e-05	0.0004	CcSEcCtD
Nefazodone—Abdominal distension—Doxorubicin—kidney cancer	8.22e-05	0.000399	CcSEcCtD
Nefazodone—Hypotension—Paclitaxel—kidney cancer	8.21e-05	0.000399	CcSEcCtD
Nefazodone—Ill-defined disorder—Capecitabine—kidney cancer	8.19e-05	0.000398	CcSEcCtD
Nefazodone—Headache—Sunitinib—kidney cancer	8.19e-05	0.000398	CcSEcCtD
Nefazodone—Asthma—Doxorubicin—kidney cancer	8.17e-05	0.000397	CcSEcCtD
Nefazodone—Influenza—Doxorubicin—kidney cancer	8.17e-05	0.000397	CcSEcCtD
Nefazodone—Dysphagia—Doxorubicin—kidney cancer	8.17e-05	0.000397	CcSEcCtD
Nefazodone—Anaemia—Capecitabine—kidney cancer	8.16e-05	0.000396	CcSEcCtD
Nefazodone—Hypersensitivity—Vincristine—kidney cancer	8.15e-05	0.000396	CcSEcCtD
Nefazodone—Nausea—Sorafenib—kidney cancer	8.07e-05	0.000392	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Paclitaxel—kidney cancer	8e-05	0.000389	CcSEcCtD
Nefazodone—Malaise—Capecitabine—kidney cancer	7.96e-05	0.000387	CcSEcCtD
Nefazodone—Angina pectoris—Doxorubicin—kidney cancer	7.96e-05	0.000387	CcSEcCtD
Nefazodone—Insomnia—Paclitaxel—kidney cancer	7.94e-05	0.000386	CcSEcCtD
Nefazodone—Vertigo—Capecitabine—kidney cancer	7.93e-05	0.000385	CcSEcCtD
Nefazodone—Asthenia—Vincristine—kidney cancer	7.93e-05	0.000385	CcSEcCtD
Nefazodone—Syncope—Capecitabine—kidney cancer	7.92e-05	0.000385	CcSEcCtD
Nefazodone—Leukopenia—Capecitabine—kidney cancer	7.9e-05	0.000384	CcSEcCtD
Nefazodone—Paraesthesia—Paclitaxel—kidney cancer	7.89e-05	0.000383	CcSEcCtD
Nefazodone—Vomiting—Dactinomycin—kidney cancer	7.87e-05	0.000382	CcSEcCtD
Nefazodone—Bronchitis—Doxorubicin—kidney cancer	7.86e-05	0.000382	CcSEcCtD
Nefazodone—Dyspnoea—Paclitaxel—kidney cancer	7.83e-05	0.00038	CcSEcCtD
Nefazodone—Somnolence—Paclitaxel—kidney cancer	7.81e-05	0.000379	CcSEcCtD
Nefazodone—Palpitations—Capecitabine—kidney cancer	7.8e-05	0.000379	CcSEcCtD
Nefazodone—Rash—Dactinomycin—kidney cancer	7.8e-05	0.000379	CcSEcCtD
Nefazodone—Nausea—Sunitinib—kidney cancer	7.76e-05	0.000377	CcSEcCtD
Nefazodone—Loss of consciousness—Capecitabine—kidney cancer	7.76e-05	0.000377	CcSEcCtD
Nefazodone—Dyspepsia—Paclitaxel—kidney cancer	7.73e-05	0.000375	CcSEcCtD
Nefazodone—Cough—Capecitabine—kidney cancer	7.71e-05	0.000374	CcSEcCtD
Nefazodone—Dysuria—Doxorubicin—kidney cancer	7.64e-05	0.000371	CcSEcCtD
Nefazodone—Decreased appetite—Paclitaxel—kidney cancer	7.63e-05	0.000371	CcSEcCtD
Nefazodone—Hypertension—Capecitabine—kidney cancer	7.62e-05	0.00037	CcSEcCtD
Nefazodone—Diarrhoea—Vincristine—kidney cancer	7.56e-05	0.000367	CcSEcCtD
Nefazodone—Pollakiuria—Doxorubicin—kidney cancer	7.55e-05	0.000367	CcSEcCtD
Nefazodone—Asthenia—Gemcitabine—kidney cancer	7.53e-05	0.000366	CcSEcCtD
Nefazodone—Myalgia—Capecitabine—kidney cancer	7.52e-05	0.000365	CcSEcCtD
Nefazodone—Arthralgia—Capecitabine—kidney cancer	7.52e-05	0.000365	CcSEcCtD
Nefazodone—Chest pain—Capecitabine—kidney cancer	7.52e-05	0.000365	CcSEcCtD
Nefazodone—Pain—Paclitaxel—kidney cancer	7.51e-05	0.000365	CcSEcCtD
Nefazodone—Constipation—Paclitaxel—kidney cancer	7.51e-05	0.000365	CcSEcCtD
Nefazodone—Anxiety—Capecitabine—kidney cancer	7.49e-05	0.000364	CcSEcCtD
Nefazodone—Photosensitivity reaction—Doxorubicin—kidney cancer	7.46e-05	0.000362	CcSEcCtD
Nefazodone—Weight increased—Doxorubicin—kidney cancer	7.43e-05	0.000361	CcSEcCtD
Nefazodone—Discomfort—Capecitabine—kidney cancer	7.43e-05	0.000361	CcSEcCtD
Nefazodone—Pruritus—Gemcitabine—kidney cancer	7.42e-05	0.00036	CcSEcCtD
Nefazodone—Weight decreased—Doxorubicin—kidney cancer	7.39e-05	0.000359	CcSEcCtD
Nefazodone—Dry mouth—Capecitabine—kidney cancer	7.35e-05	0.000357	CcSEcCtD
Nefazodone—Nausea—Dactinomycin—kidney cancer	7.35e-05	0.000357	CcSEcCtD
Nefazodone—Pneumonia—Doxorubicin—kidney cancer	7.33e-05	0.000356	CcSEcCtD
Nefazodone—Dizziness—Vincristine—kidney cancer	7.31e-05	0.000355	CcSEcCtD
Nefazodone—Confusional state—Capecitabine—kidney cancer	7.27e-05	0.000353	CcSEcCtD
Nefazodone—Feeling abnormal—Paclitaxel—kidney cancer	7.24e-05	0.000352	CcSEcCtD
Nefazodone—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	7.22e-05	0.000351	CcSEcCtD
Nefazodone—Oedema—Capecitabine—kidney cancer	7.21e-05	0.00035	CcSEcCtD
Nefazodone—Gastrointestinal pain—Paclitaxel—kidney cancer	7.18e-05	0.000349	CcSEcCtD
Nefazodone—Diarrhoea—Gemcitabine—kidney cancer	7.18e-05	0.000349	CcSEcCtD
Nefazodone—Infection—Capecitabine—kidney cancer	7.16e-05	0.000348	CcSEcCtD
Nefazodone—Stomatitis—Doxorubicin—kidney cancer	7.1e-05	0.000345	CcSEcCtD
Nefazodone—Shock—Capecitabine—kidney cancer	7.09e-05	0.000344	CcSEcCtD
Nefazodone—Conjunctivitis—Doxorubicin—kidney cancer	7.08e-05	0.000344	CcSEcCtD
Nefazodone—Urinary tract infection—Doxorubicin—kidney cancer	7.08e-05	0.000344	CcSEcCtD
Nefazodone—Thrombocytopenia—Capecitabine—kidney cancer	7.06e-05	0.000343	CcSEcCtD
Nefazodone—Tachycardia—Capecitabine—kidney cancer	7.03e-05	0.000342	CcSEcCtD
Nefazodone—Vomiting—Vincristine—kidney cancer	7.03e-05	0.000341	CcSEcCtD
Nefazodone—Sweating—Doxorubicin—kidney cancer	6.98e-05	0.000339	CcSEcCtD
Nefazodone—Urticaria—Paclitaxel—kidney cancer	6.98e-05	0.000339	CcSEcCtD
Nefazodone—Rash—Vincristine—kidney cancer	6.97e-05	0.000339	CcSEcCtD
Nefazodone—Hyperhidrosis—Capecitabine—kidney cancer	6.97e-05	0.000338	CcSEcCtD
Nefazodone—Dermatitis—Vincristine—kidney cancer	6.96e-05	0.000338	CcSEcCtD
Nefazodone—Haematuria—Doxorubicin—kidney cancer	6.94e-05	0.000337	CcSEcCtD
Nefazodone—Abdominal pain—Paclitaxel—kidney cancer	6.94e-05	0.000337	CcSEcCtD
Nefazodone—Body temperature increased—Paclitaxel—kidney cancer	6.94e-05	0.000337	CcSEcCtD
Nefazodone—Headache—Vincristine—kidney cancer	6.93e-05	0.000336	CcSEcCtD
Nefazodone—Epistaxis—Doxorubicin—kidney cancer	6.87e-05	0.000334	CcSEcCtD
Nefazodone—Anorexia—Capecitabine—kidney cancer	6.87e-05	0.000334	CcSEcCtD
Nefazodone—Sinusitis—Doxorubicin—kidney cancer	6.83e-05	0.000332	CcSEcCtD
Nefazodone—Hypotension—Capecitabine—kidney cancer	6.73e-05	0.000327	CcSEcCtD
Nefazodone—Vomiting—Gemcitabine—kidney cancer	6.67e-05	0.000324	CcSEcCtD
Nefazodone—Bradycardia—Doxorubicin—kidney cancer	6.66e-05	0.000323	CcSEcCtD
Nefazodone—Rash—Gemcitabine—kidney cancer	6.61e-05	0.000321	CcSEcCtD
Nefazodone—Dermatitis—Gemcitabine—kidney cancer	6.61e-05	0.000321	CcSEcCtD
Nefazodone—Haemoglobin—Doxorubicin—kidney cancer	6.57e-05	0.000319	CcSEcCtD
Nefazodone—Headache—Gemcitabine—kidney cancer	6.57e-05	0.000319	CcSEcCtD
Nefazodone—Nausea—Vincristine—kidney cancer	6.57e-05	0.000319	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Capecitabine—kidney cancer	6.57e-05	0.000319	CcSEcCtD
Nefazodone—Rhinitis—Doxorubicin—kidney cancer	6.56e-05	0.000318	CcSEcCtD
Nefazodone—Hepatitis—Doxorubicin—kidney cancer	6.54e-05	0.000318	CcSEcCtD
Nefazodone—Haemorrhage—Doxorubicin—kidney cancer	6.54e-05	0.000318	CcSEcCtD
Nefazodone—Insomnia—Capecitabine—kidney cancer	6.52e-05	0.000317	CcSEcCtD
Nefazodone—Hypoaesthesia—Doxorubicin—kidney cancer	6.51e-05	0.000316	CcSEcCtD
Nefazodone—Pharyngitis—Doxorubicin—kidney cancer	6.49e-05	0.000315	CcSEcCtD
Nefazodone—Paraesthesia—Capecitabine—kidney cancer	6.47e-05	0.000314	CcSEcCtD
Nefazodone—Hypersensitivity—Paclitaxel—kidney cancer	6.47e-05	0.000314	CcSEcCtD
Nefazodone—Oedema peripheral—Doxorubicin—kidney cancer	6.44e-05	0.000313	CcSEcCtD
Nefazodone—Dyspnoea—Capecitabine—kidney cancer	6.42e-05	0.000312	CcSEcCtD
Nefazodone—Dyspepsia—Capecitabine—kidney cancer	6.34e-05	0.000308	CcSEcCtD
Nefazodone—Visual impairment—Doxorubicin—kidney cancer	6.3e-05	0.000306	CcSEcCtD
Nefazodone—Asthenia—Paclitaxel—kidney cancer	6.3e-05	0.000306	CcSEcCtD
Nefazodone—Decreased appetite—Capecitabine—kidney cancer	6.26e-05	0.000304	CcSEcCtD
Nefazodone—Nausea—Gemcitabine—kidney cancer	6.23e-05	0.000303	CcSEcCtD
Nefazodone—Pruritus—Paclitaxel—kidney cancer	6.21e-05	0.000302	CcSEcCtD
Nefazodone—Erythema multiforme—Doxorubicin—kidney cancer	6.18e-05	0.0003	CcSEcCtD
Nefazodone—Pain—Capecitabine—kidney cancer	6.16e-05	0.000299	CcSEcCtD
Nefazodone—Constipation—Capecitabine—kidney cancer	6.16e-05	0.000299	CcSEcCtD
Nefazodone—Tinnitus—Doxorubicin—kidney cancer	6.1e-05	0.000296	CcSEcCtD
Nefazodone—Flushing—Doxorubicin—kidney cancer	6.07e-05	0.000295	CcSEcCtD
Nefazodone—Diarrhoea—Paclitaxel—kidney cancer	6.01e-05	0.000292	CcSEcCtD
Nefazodone—Feeling abnormal—Capecitabine—kidney cancer	5.94e-05	0.000288	CcSEcCtD
Nefazodone—Gastrointestinal pain—Capecitabine—kidney cancer	5.89e-05	0.000286	CcSEcCtD
Nefazodone—Chills—Doxorubicin—kidney cancer	5.87e-05	0.000285	CcSEcCtD
Nefazodone—Dizziness—Paclitaxel—kidney cancer	5.81e-05	0.000282	CcSEcCtD
Nefazodone—Alopecia—Doxorubicin—kidney cancer	5.78e-05	0.000281	CcSEcCtD
Nefazodone—Urticaria—Capecitabine—kidney cancer	5.73e-05	0.000278	CcSEcCtD
Nefazodone—Abdominal pain—Capecitabine—kidney cancer	5.7e-05	0.000277	CcSEcCtD
Nefazodone—Body temperature increased—Capecitabine—kidney cancer	5.7e-05	0.000277	CcSEcCtD
Nefazodone—Flatulence—Doxorubicin—kidney cancer	5.61e-05	0.000272	CcSEcCtD
Nefazodone—Vomiting—Paclitaxel—kidney cancer	5.58e-05	0.000271	CcSEcCtD
Nefazodone—Dysgeusia—Doxorubicin—kidney cancer	5.57e-05	0.000271	CcSEcCtD
Nefazodone—Rash—Paclitaxel—kidney cancer	5.54e-05	0.000269	CcSEcCtD
Nefazodone—Dermatitis—Paclitaxel—kidney cancer	5.53e-05	0.000269	CcSEcCtD
Nefazodone—Back pain—Doxorubicin—kidney cancer	5.51e-05	0.000267	CcSEcCtD
Nefazodone—Headache—Paclitaxel—kidney cancer	5.5e-05	0.000267	CcSEcCtD
Nefazodone—Muscle spasms—Doxorubicin—kidney cancer	5.47e-05	0.000266	CcSEcCtD
Nefazodone—Vision blurred—Doxorubicin—kidney cancer	5.36e-05	0.000261	CcSEcCtD
Nefazodone—Hypersensitivity—Capecitabine—kidney cancer	5.31e-05	0.000258	CcSEcCtD
Nefazodone—Ill-defined disorder—Doxorubicin—kidney cancer	5.28e-05	0.000257	CcSEcCtD
Nefazodone—Anaemia—Doxorubicin—kidney cancer	5.26e-05	0.000256	CcSEcCtD
Nefazodone—Agitation—Doxorubicin—kidney cancer	5.23e-05	0.000254	CcSEcCtD
Nefazodone—Nausea—Paclitaxel—kidney cancer	5.22e-05	0.000253	CcSEcCtD
Nefazodone—Asthenia—Capecitabine—kidney cancer	5.17e-05	0.000251	CcSEcCtD
Nefazodone—Malaise—Doxorubicin—kidney cancer	5.13e-05	0.000249	CcSEcCtD
Nefazodone—Vertigo—Doxorubicin—kidney cancer	5.11e-05	0.000248	CcSEcCtD
Nefazodone—Syncope—Doxorubicin—kidney cancer	5.1e-05	0.000248	CcSEcCtD
Nefazodone—Pruritus—Capecitabine—kidney cancer	5.1e-05	0.000248	CcSEcCtD
Nefazodone—Leukopenia—Doxorubicin—kidney cancer	5.09e-05	0.000247	CcSEcCtD
Nefazodone—Palpitations—Doxorubicin—kidney cancer	5.03e-05	0.000244	CcSEcCtD
Nefazodone—Loss of consciousness—Doxorubicin—kidney cancer	5e-05	0.000243	CcSEcCtD
Nefazodone—Cough—Doxorubicin—kidney cancer	4.97e-05	0.000241	CcSEcCtD
Nefazodone—Convulsion—Doxorubicin—kidney cancer	4.93e-05	0.00024	CcSEcCtD
Nefazodone—Diarrhoea—Capecitabine—kidney cancer	4.93e-05	0.00024	CcSEcCtD
Nefazodone—Hypertension—Doxorubicin—kidney cancer	4.91e-05	0.000239	CcSEcCtD
Nefazodone—Chest pain—Doxorubicin—kidney cancer	4.85e-05	0.000235	CcSEcCtD
Nefazodone—Myalgia—Doxorubicin—kidney cancer	4.85e-05	0.000235	CcSEcCtD
Nefazodone—Arthralgia—Doxorubicin—kidney cancer	4.85e-05	0.000235	CcSEcCtD
Nefazodone—Anxiety—Doxorubicin—kidney cancer	4.83e-05	0.000235	CcSEcCtD
Nefazodone—Discomfort—Doxorubicin—kidney cancer	4.79e-05	0.000233	CcSEcCtD
Nefazodone—Dizziness—Capecitabine—kidney cancer	4.77e-05	0.000231	CcSEcCtD
Nefazodone—Dry mouth—Doxorubicin—kidney cancer	4.74e-05	0.00023	CcSEcCtD
Nefazodone—Confusional state—Doxorubicin—kidney cancer	4.68e-05	0.000228	CcSEcCtD
Nefazodone—Anaphylactic shock—Doxorubicin—kidney cancer	4.65e-05	0.000226	CcSEcCtD
Nefazodone—Oedema—Doxorubicin—kidney cancer	4.65e-05	0.000226	CcSEcCtD
Nefazodone—Infection—Doxorubicin—kidney cancer	4.61e-05	0.000224	CcSEcCtD
Nefazodone—Vomiting—Capecitabine—kidney cancer	4.58e-05	0.000223	CcSEcCtD
Nefazodone—Shock—Doxorubicin—kidney cancer	4.57e-05	0.000222	CcSEcCtD
Nefazodone—Thrombocytopenia—Doxorubicin—kidney cancer	4.55e-05	0.000221	CcSEcCtD
Nefazodone—Rash—Capecitabine—kidney cancer	4.54e-05	0.000221	CcSEcCtD
Nefazodone—Dermatitis—Capecitabine—kidney cancer	4.54e-05	0.000221	CcSEcCtD
Nefazodone—Tachycardia—Doxorubicin—kidney cancer	4.53e-05	0.00022	CcSEcCtD
Nefazodone—Headache—Capecitabine—kidney cancer	4.51e-05	0.000219	CcSEcCtD
Nefazodone—Hyperhidrosis—Doxorubicin—kidney cancer	4.49e-05	0.000218	CcSEcCtD
Nefazodone—Anorexia—Doxorubicin—kidney cancer	4.43e-05	0.000215	CcSEcCtD
Nefazodone—Hypotension—Doxorubicin—kidney cancer	4.34e-05	0.000211	CcSEcCtD
Nefazodone—Nausea—Capecitabine—kidney cancer	4.28e-05	0.000208	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Doxorubicin—kidney cancer	4.23e-05	0.000206	CcSEcCtD
Nefazodone—Insomnia—Doxorubicin—kidney cancer	4.2e-05	0.000204	CcSEcCtD
Nefazodone—Paraesthesia—Doxorubicin—kidney cancer	4.17e-05	0.000203	CcSEcCtD
Nefazodone—Dyspnoea—Doxorubicin—kidney cancer	4.14e-05	0.000201	CcSEcCtD
Nefazodone—Somnolence—Doxorubicin—kidney cancer	4.13e-05	0.000201	CcSEcCtD
Nefazodone—Dyspepsia—Doxorubicin—kidney cancer	4.09e-05	0.000199	CcSEcCtD
Nefazodone—Decreased appetite—Doxorubicin—kidney cancer	4.04e-05	0.000196	CcSEcCtD
Nefazodone—Constipation—Doxorubicin—kidney cancer	3.97e-05	0.000193	CcSEcCtD
Nefazodone—Pain—Doxorubicin—kidney cancer	3.97e-05	0.000193	CcSEcCtD
Nefazodone—Feeling abnormal—Doxorubicin—kidney cancer	3.83e-05	0.000186	CcSEcCtD
Nefazodone—Gastrointestinal pain—Doxorubicin—kidney cancer	3.8e-05	0.000185	CcSEcCtD
Nefazodone—Urticaria—Doxorubicin—kidney cancer	3.69e-05	0.000179	CcSEcCtD
Nefazodone—Abdominal pain—Doxorubicin—kidney cancer	3.67e-05	0.000178	CcSEcCtD
Nefazodone—Body temperature increased—Doxorubicin—kidney cancer	3.67e-05	0.000178	CcSEcCtD
Nefazodone—Hypersensitivity—Doxorubicin—kidney cancer	3.42e-05	0.000166	CcSEcCtD
Nefazodone—Asthenia—Doxorubicin—kidney cancer	3.33e-05	0.000162	CcSEcCtD
Nefazodone—Pruritus—Doxorubicin—kidney cancer	3.29e-05	0.00016	CcSEcCtD
Nefazodone—Diarrhoea—Doxorubicin—kidney cancer	3.18e-05	0.000154	CcSEcCtD
Nefazodone—Dizziness—Doxorubicin—kidney cancer	3.07e-05	0.000149	CcSEcCtD
Nefazodone—Vomiting—Doxorubicin—kidney cancer	2.95e-05	0.000143	CcSEcCtD
Nefazodone—Rash—Doxorubicin—kidney cancer	2.93e-05	0.000142	CcSEcCtD
Nefazodone—Dermatitis—Doxorubicin—kidney cancer	2.93e-05	0.000142	CcSEcCtD
Nefazodone—Headache—Doxorubicin—kidney cancer	2.91e-05	0.000141	CcSEcCtD
Nefazodone—Nausea—Doxorubicin—kidney cancer	2.76e-05	0.000134	CcSEcCtD
Nefazodone—Domperidone—ABCB1—kidney cancer	2.72e-05	0.241	CrCbGaD
Nefazodone—Aripiprazole—ABCB1—kidney cancer	2.1e-05	0.186	CrCbGaD
Nefazodone—Trazodone—ABCB1—kidney cancer	2.09e-05	0.185	CrCbGaD
Nefazodone—Fluphenazine—ABCB1—kidney cancer	1.69e-05	0.15	CrCbGaD
Nefazodone—Trifluoperazine—ABCB1—kidney cancer	1.35e-05	0.12	CrCbGaD
Nefazodone—Quetiapine—ABCB1—kidney cancer	1.31e-05	0.116	CrCbGaD
Nefazodone—CYP3A5—Metabolism—ABCB1—kidney cancer	5.34e-06	0.000168	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—IL2—kidney cancer	5.33e-06	0.000167	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IGF1R—kidney cancer	5.33e-06	0.000167	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PSMD7—kidney cancer	5.32e-06	0.000167	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—IL2—kidney cancer	5.3e-06	0.000166	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—SLC5A5—kidney cancer	5.29e-06	0.000166	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—KRAS—kidney cancer	5.27e-06	0.000165	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CA9—kidney cancer	5.25e-06	0.000165	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IGF1R—kidney cancer	5.21e-06	0.000164	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—GSTM1—kidney cancer	5.19e-06	0.000163	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—RAF1—kidney cancer	5.13e-06	0.000161	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—SLC2A1—kidney cancer	5.11e-06	0.00016	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—HIF1A—kidney cancer	5.08e-06	0.000159	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—IL2—kidney cancer	5.07e-06	0.000159	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—POMC—kidney cancer	5.07e-06	0.000159	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—IL2—kidney cancer	5.07e-06	0.000159	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—TSC2—kidney cancer	5.06e-06	0.000159	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—HIF1A—kidney cancer	5.05e-06	0.000158	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—BCHE—kidney cancer	5.04e-06	0.000158	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—TSC2—kidney cancer	5.04e-06	0.000158	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—RAF1—kidney cancer	5.02e-06	0.000158	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IGF2—kidney cancer	5.01e-06	0.000157	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CDKN2B—kidney cancer	4.99e-06	0.000157	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—SLC5A5—kidney cancer	4.98e-06	0.000156	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—IL2—kidney cancer	4.96e-06	0.000156	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—CYP1A1—kidney cancer	4.92e-06	0.000154	CbGpPWpGaD
Nefazodone—ABCB1—Transmembrane transport of small molecules—RAF1—kidney cancer	4.87e-06	0.000153	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—KDR—kidney cancer	4.85e-06	0.000152	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IGF1R—kidney cancer	4.85e-06	0.000152	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—PIK3CA—kidney cancer	4.84e-06	0.000152	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—HIF1A—kidney cancer	4.83e-06	0.000152	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—KDR—kidney cancer	4.83e-06	0.000152	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—TSC2—kidney cancer	4.82e-06	0.000151	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—SLC2A1—kidney cancer	4.81e-06	0.000151	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—TP53—kidney cancer	4.68e-06	0.000147	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—RAF1—kidney cancer	4.67e-06	0.000147	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—KDR—kidney cancer	4.62e-06	0.000145	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—IL2—kidney cancer	4.61e-06	0.000145	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—IL2—kidney cancer	4.6e-06	0.000144	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—IL2—kidney cancer	4.51e-06	0.000141	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—KIT—kidney cancer	4.47e-06	0.00014	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—APC—kidney cancer	4.47e-06	0.00014	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CRABP1—kidney cancer	4.47e-06	0.00014	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—APC—kidney cancer	4.45e-06	0.00014	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—KIT—kidney cancer	4.45e-06	0.00014	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—HIF1A—kidney cancer	4.38e-06	0.000138	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—TSC2—kidney cancer	4.37e-06	0.000137	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—HIF1A—kidney cancer	4.29e-06	0.000135	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—TSC2—kidney cancer	4.28e-06	0.000134	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—MAPK3—kidney cancer	4.28e-06	0.000134	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—MAPK3—kidney cancer	4.26e-06	0.000134	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—GSTP1—kidney cancer	4.26e-06	0.000134	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—APC—kidney cancer	4.26e-06	0.000134	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—KIT—kidney cancer	4.26e-06	0.000134	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—POMC—kidney cancer	4.26e-06	0.000134	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—POMC—kidney cancer	4.23e-06	0.000133	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—BRAF—kidney cancer	4.2e-06	0.000132	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—KDR—kidney cancer	4.19e-06	0.000132	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—IL2—kidney cancer	4.19e-06	0.000131	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—BRAF—kidney cancer	4.18e-06	0.000131	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ITPR2—kidney cancer	4.15e-06	0.00013	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—KDR—kidney cancer	4.11e-06	0.000129	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—MAPK3—kidney cancer	4.08e-06	0.000128	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—MAPK1—kidney cancer	4.07e-06	0.000128	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—MAPK1—kidney cancer	4.05e-06	0.000127	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—POMC—kidney cancer	4.05e-06	0.000127	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—PTGS2—kidney cancer	4.05e-06	0.000127	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—GSTP1—kidney cancer	4.01e-06	0.000126	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—BRAF—kidney cancer	4e-06	0.000126	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—POMC—kidney cancer	4e-06	0.000126	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—HIF1A—kidney cancer	3.99e-06	0.000125	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TSC2—kidney cancer	3.98e-06	0.000125	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—GSTM1—kidney cancer	3.91e-06	0.000123	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—PIK3CA—kidney cancer	3.89e-06	0.000122	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—MAPK1—kidney cancer	3.88e-06	0.000122	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—PIK3CA—kidney cancer	3.87e-06	0.000122	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—KIT—kidney cancer	3.86e-06	0.000121	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—APC—kidney cancer	3.86e-06	0.000121	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—KRAS—kidney cancer	3.85e-06	0.000121	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—KRAS—kidney cancer	3.83e-06	0.00012	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—KDR—kidney cancer	3.81e-06	0.00012	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—ABCB1—kidney cancer	3.8e-06	0.000119	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ACHE—kidney cancer	3.79e-06	0.000119	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GSTT1—kidney cancer	3.79e-06	0.000119	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—KIT—kidney cancer	3.78e-06	0.000119	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—APC—kidney cancer	3.78e-06	0.000119	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—CYP1A1—kidney cancer	3.71e-06	0.000116	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—PIK3CA—kidney cancer	3.71e-06	0.000116	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—MAPK3—kidney cancer	3.7e-06	0.000116	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—GSTM1—kidney cancer	3.69e-06	0.000116	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—POMC—kidney cancer	3.68e-06	0.000115	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—POMC—kidney cancer	3.67e-06	0.000115	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—KRAS—kidney cancer	3.66e-06	0.000115	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—BRAF—kidney cancer	3.63e-06	0.000114	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—MAPK3—kidney cancer	3.62e-06	0.000114	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—POMC—kidney cancer	3.6e-06	0.000113	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—SCARB1—kidney cancer	3.58e-06	0.000112	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—BRAF—kidney cancer	3.56e-06	0.000112	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PTGS1—kidney cancer	3.55e-06	0.000111	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—PIK3CA—kidney cancer	3.54e-06	0.000111	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—PTEN—kidney cancer	3.53e-06	0.000111	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—MAPK1—kidney cancer	3.52e-06	0.00011	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—PIK3CA—kidney cancer	3.52e-06	0.00011	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—APC—kidney cancer	3.51e-06	0.00011	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—KIT—kidney cancer	3.51e-06	0.00011	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—RAF1—kidney cancer	3.51e-06	0.00011	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—CYP1A1—kidney cancer	3.5e-06	0.00011	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—RELA—kidney cancer	3.49e-06	0.00011	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—RAF1—kidney cancer	3.49e-06	0.00011	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PSMD7—kidney cancer	3.48e-06	0.000109	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—RELA—kidney cancer	3.48e-06	0.000109	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—ERBB2—kidney cancer	3.47e-06	0.000109	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—ERBB2—kidney cancer	3.45e-06	0.000108	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—MAPK1—kidney cancer	3.45e-06	0.000108	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MTOR—kidney cancer	3.43e-06	0.000108	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MTOR—kidney cancer	3.41e-06	0.000107	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—PIK3CA—kidney cancer	3.37e-06	0.000106	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—MAPK3—kidney cancer	3.37e-06	0.000106	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—PIK3CA—kidney cancer	3.36e-06	0.000106	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—POMC—kidney cancer	3.34e-06	0.000105	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—RAF1—kidney cancer	3.34e-06	0.000105	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—RELA—kidney cancer	3.33e-06	0.000104	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—KRAS—kidney cancer	3.32e-06	0.000104	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—ERBB2—kidney cancer	3.31e-06	0.000104	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—BRAF—kidney cancer	3.3e-06	0.000104	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—BCHE—kidney cancer	3.3e-06	0.000104	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—PIK3CA—kidney cancer	3.29e-06	0.000103	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MTOR—kidney cancer	3.26e-06	0.000102	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—SLC5A5—kidney cancer	3.26e-06	0.000102	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—KRAS—kidney cancer	3.26e-06	0.000102	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CDKN1B—kidney cancer	3.22e-06	0.000101	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—MAPK1—kidney cancer	3.2e-06	0.000101	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CDKN1B—kidney cancer	3.2e-06	0.0001	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PTGS2—kidney cancer	3.19e-06	0.0001	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—IL2—kidney cancer	3.15e-06	9.88e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—SLC2A1—kidney cancer	3.15e-06	9.87e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—IL2—kidney cancer	3.13e-06	9.82e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CCND1—kidney cancer	3.07e-06	9.63e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CDKN1B—kidney cancer	3.06e-06	9.61e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—JUN—kidney cancer	3.06e-06	9.61e-05	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—PIK3CA—kidney cancer	3.06e-06	9.6e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—PIK3CA—kidney cancer	3.05e-06	9.59e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CCND1—kidney cancer	3.05e-06	9.58e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—JUN—kidney cancer	3.04e-06	9.56e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CTNNB1—kidney cancer	3.04e-06	9.53e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—RAF1—kidney cancer	3.03e-06	9.51e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—KRAS—kidney cancer	3.02e-06	9.49e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CTNNB1—kidney cancer	3.02e-06	9.48e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—RELA—kidney cancer	3.02e-06	9.47e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—ERBB2—kidney cancer	3e-06	9.41e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—IL2—kidney cancer	3e-06	9.4e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—PIK3CA—kidney cancer	2.99e-06	9.39e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—RAF1—kidney cancer	2.97e-06	9.32e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—PTEN—kidney cancer	2.96e-06	9.29e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MTOR—kidney cancer	2.96e-06	9.29e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—RELA—kidney cancer	2.96e-06	9.28e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—PTEN—kidney cancer	2.95e-06	9.24e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—ERBB2—kidney cancer	2.94e-06	9.22e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PTGS2—kidney cancer	2.92e-06	9.18e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CCND1—kidney cancer	2.92e-06	9.17e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—JUN—kidney cancer	2.91e-06	9.15e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MTOR—kidney cancer	2.9e-06	9.1e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CTNNB1—kidney cancer	2.89e-06	9.08e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PTEN—kidney cancer	2.82e-06	8.85e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PTEN—kidney cancer	2.78e-06	8.73e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—PIK3CA—kidney cancer	2.78e-06	8.72e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CDKN1B—kidney cancer	2.78e-06	8.72e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—POMC—kidney cancer	2.77e-06	8.68e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—RAF1—kidney cancer	2.76e-06	8.66e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—RELA—kidney cancer	2.75e-06	8.62e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—ERBB2—kidney cancer	2.73e-06	8.56e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CDKN1B—kidney cancer	2.72e-06	8.54e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IL2—kidney cancer	2.72e-06	8.53e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MTOR—kidney cancer	2.69e-06	8.45e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—VEGFA—kidney cancer	2.67e-06	8.39e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IL2—kidney cancer	2.66e-06	8.35e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—VEGFA—kidney cancer	2.66e-06	8.35e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CCND1—kidney cancer	2.65e-06	8.32e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—JUN—kidney cancer	2.64e-06	8.3e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CTNNB1—kidney cancer	2.62e-06	8.24e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GSTP1—kidney cancer	2.62e-06	8.24e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—POMC—kidney cancer	2.61e-06	8.18e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CCND1—kidney cancer	2.59e-06	8.14e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—JUN—kidney cancer	2.59e-06	8.13e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CTNNB1—kidney cancer	2.57e-06	8.06e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PTEN—kidney cancer	2.56e-06	8.03e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PTEN—kidney cancer	2.55e-06	8e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—VEGFA—kidney cancer	2.55e-06	7.99e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MAPK3—kidney cancer	2.53e-06	7.94e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CDKN1B—kidney cancer	2.53e-06	7.93e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MAPK3—kidney cancer	2.52e-06	7.9e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PTEN—kidney cancer	2.5e-06	7.86e-05	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—PIK3CA—kidney cancer	2.49e-06	7.81e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ABCB1—kidney cancer	2.48e-06	7.8e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IL2—kidney cancer	2.47e-06	7.76e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MYC—kidney cancer	2.46e-06	7.72e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MYC—kidney cancer	2.45e-06	7.68e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GSTM1—kidney cancer	2.41e-06	7.57e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CCND1—kidney cancer	2.41e-06	7.57e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MAPK3—kidney cancer	2.41e-06	7.56e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MAPK1—kidney cancer	2.41e-06	7.55e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—JUN—kidney cancer	2.41e-06	7.55e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MAPK1—kidney cancer	2.39e-06	7.52e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CTNNB1—kidney cancer	2.39e-06	7.49e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MYC—kidney cancer	2.34e-06	7.35e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PTEN—kidney cancer	2.33e-06	7.3e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—VEGFA—kidney cancer	2.31e-06	7.25e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MAPK1—kidney cancer	2.29e-06	7.19e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CYP1A1—kidney cancer	2.29e-06	7.17e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—KRAS—kidney cancer	2.27e-06	7.13e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—VEGFA—kidney cancer	2.26e-06	7.1e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—KRAS—kidney cancer	2.26e-06	7.1e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PTGS2—kidney cancer	2.21e-06	6.93e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MAPK3—kidney cancer	2.19e-06	6.86e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—KRAS—kidney cancer	2.16e-06	6.79e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MAPK3—kidney cancer	2.14e-06	6.72e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MYC—kidney cancer	2.13e-06	6.67e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—VEGFA—kidney cancer	2.1e-06	6.6e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—PIK3CA—kidney cancer	2.09e-06	6.55e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MYC—kidney cancer	2.08e-06	6.53e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MAPK1—kidney cancer	2.08e-06	6.53e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PTGS2—kidney cancer	2.08e-06	6.53e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—PIK3CA—kidney cancer	2.08e-06	6.52e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MAPK1—kidney cancer	2.04e-06	6.39e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—TP53—kidney cancer	2.02e-06	6.34e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—TP53—kidney cancer	2.01e-06	6.31e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PIK3CA—kidney cancer	1.99e-06	6.24e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MAPK3—kidney cancer	1.99e-06	6.24e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—KRAS—kidney cancer	1.96e-06	6.16e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PIK3CA—kidney cancer	1.96e-06	6.16e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MYC—kidney cancer	1.93e-06	6.07e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PTEN—kidney cancer	1.92e-06	6.04e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—TP53—kidney cancer	1.92e-06	6.04e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—KRAS—kidney cancer	1.92e-06	6.04e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MAPK1—kidney cancer	1.89e-06	5.94e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PTEN—kidney cancer	1.81e-06	5.69e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PIK3CA—kidney cancer	1.8e-06	5.66e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PIK3CA—kidney cancer	1.8e-06	5.65e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—KRAS—kidney cancer	1.79e-06	5.61e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PIK3CA—kidney cancer	1.77e-06	5.54e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—TP53—kidney cancer	1.75e-06	5.48e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—TP53—kidney cancer	1.71e-06	5.36e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—POMC—kidney cancer	1.7e-06	5.35e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PIK3CA—kidney cancer	1.64e-06	5.15e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TP53—kidney cancer	1.59e-06	4.98e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PTGS2—kidney cancer	1.36e-06	4.27e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PIK3CA—kidney cancer	1.36e-06	4.26e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PIK3CA—kidney cancer	1.28e-06	4.01e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PTEN—kidney cancer	1.19e-06	3.72e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PIK3CA—kidney cancer	8.36e-07	2.62e-05	CbGpPWpGaD
